Order Article Reprints

Völter F, Mittlmeier L, Gosewisch A, Brosch-Lenz J, Gildehaus FJ, Zacherl MJ, Beyer L, Stief CG, Holzgreve A, Rübenthaler J, et al. Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after ¹⁷⁷Lu-PSMA-617 Radioligand Therapy. Diagnostics. 2021; 11(3):428. https://doi.org/10.3390/diagnostics11030428

Völter, Friederike, Lena Mittlmeier, Astrid Gosewisch, Julia Brosch-Lenz, Franz Josef Gildehaus, Mathias Johannes Zacherl, Leonie Beyer, Christian G. Stief, Adrien Holzgreve, Johannes Rübenthaler, and et al. 2021. "Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after ¹⁷⁷Lu-PSMA-617 Radioligand Therapy" Diagnostics 11, no. 3: 428. https://doi.org/10.3390/diagnostics11030428

Völter, F., Mittlmeier, L., Gosewisch, A., Brosch-Lenz, J., Gildehaus, F. J., Zacherl, M. J., Beyer, L., Stief, C. G., Holzgreve, A., Rübenthaler, J., Cyran, C. C., Böning, G., Bartenstein, P., Todica, A., & Ilhan, H. (2021). Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after ¹⁷⁷Lu-PSMA-617 Radioligand Therapy. Diagnostics, 11(3), 428. https://doi.org/10.3390/diagnostics11030428